Laboratory parameter profiles among patients with cystic fibrosis Christopher H. Goss, Nicole Mayer-Hamblett, Richard A. Kronmal, Judy Williams, Bonnie W. Ramsey  Journal of Cystic Fibrosis  Volume 6, Issue 2, Pages 117-123 (April 2007) DOI: 10.1016/j.jcf.2006.05.012 Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions

Fig. 1 Frequency histograms showing the distribution of baseline laboratory profiles of trial subjects: (a) percent of neutrophils from complete blood count; (b) white blood cell count (WBC) (units: 109/l); (c) asparate aminotransferase (AST) in U/l; (d) alanine aminotransferase (ALT) in U/l. Journal of Cystic Fibrosis 2007 6, 117-123DOI: (10.1016/j.jcf.2006.05.012) Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions

Fig. 2 Percent of subjects at baseline with specific laboratory tests greater than or equal to grade 1 toxicity based on Common Toxicity Criteria (grades 1–3). White blood cell count (WBC), asparate aminotransferase (AST), alanine aminotransferase (ALT). Journal of Cystic Fibrosis 2007 6, 117-123DOI: (10.1016/j.jcf.2006.05.012) Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions

Fig. 3 Percent of subjects whose laboratory values of AST, ALT, hemoglobin and serum sodium changed from Common Toxicity Criteria (CTC) grade 0 to 2 during the 24 week duration of the study in the placebo arm of the study. Asparate aminotransferase (AST), alanine aminotransferase (ALT). Journal of Cystic Fibrosis 2007 6, 117-123DOI: (10.1016/j.jcf.2006.05.012) Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions

Fig. 4 Longitudinal laboratory values for a random sample of 20 placebo patients over the duration of the study for asparate aminotransferase (AST) and alanine aminotransferase (ALT). Journal of Cystic Fibrosis 2007 6, 117-123DOI: (10.1016/j.jcf.2006.05.012) Copyright © 2006 European Cystic Fibrosis Society Terms and Conditions